At a Glance
  • Status: Active Consortium
  • Year Launched: 2011
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • Disease focus:
  • Location: Europe


PREDECT aims to create more appropriate in vitro platforms for target validation and drug discovery. Laboratory platforms to validate whether target modulation would provide a clinical benefit are usually highly reductionist, often using long-established cell lines growing in two dimensions in vitro. These models do not reflect the complexity and heterogeneity of a tumor in situ, where biochemical pathways are wired with connections to the complex tumor environment provided by the stroma.


PREDECT’s goal is to compare the pathological and molecular profiles of novel in vitro platforms with those of human tumors. Because the obtention of clinical material presents both logistics and quality problems for ongoing and intense studies of target validation, PREDECT aims to use material from genetically engineered mouse models, and some “advanced” xenografts, whose pathology and molecular profiles closely match cohorts of human tumors.

Consortium History

January 2011: Project launch date
May 2012: PREDECT plenary meeting, Helsinki
March 2013: Coordinator interview in International Innovation
November 2013: PREDECT meeting, Lisbon

Structure & Governance

Coordinator: John A. Hickman, D.Sc.
Vice-coordinator: Ralph Graeser, Ph.D.
Academic coordinator: Emmy W. Verschuren, Ph.D.

PREDECT’s Scientific Advisory Board:

Mina Bissell
Lawrence Livermore Lab, Berkeley
Scientific Advisory Board chair
Bissell Lab

Alan Balmain
Balmain Lab

David Tuveson
CSH Laboratory
Tuveson lab

Pasi Jänne
Jänne Lab

Andrew Ewald
Johns Hopkins
Ewald Lab

PREDECT’s Scientific Advisory Board (SAB) first met in Florida in 2011, at the beginning of the PREDECT project, and its advice focused the program within the three pathologies. The second SAB meeting will be in Washington, DC, in April 2013, prior to the interim program review, proposed by the Innovation Medicines Initiative (IMI) for June 2013.

PREDECT’s Ethical Advisory Board is composed of Adam Smith (Nobel Foundation, London) and Erik Forsse (Karolinska Institute). The Board advises on the ethical questions regarding the use of human biological material, such as the transfer of materials between partners, and on the creation and use of animal models, particularly transgenic models, validating that appropriate local ethical permission is in place. When appropriate, the Board will advise on the use of historical clinical data.


This project is funded by the IMI, a public-private partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), resources of which are composed of financial contribution from the EU Seventh Framework Programme and EFPIA companies’ in kind contribution. Large pharmaceutical companies participating in IMI projects do not receive IMI funding. IMI contributed €8.1 million, EFPIA contributed €6.6 million in kind, and other sources contributed €2.5 million, for a total cost of €17.2 million.

Intellectual Property

The IMI intellectual property (IP) policy governs the IP regime of all projects funded by the IMI Joint Undertaking. To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk, which can be contacted by emailing The IMI IP policy can be accessed at

Data Sharing

According to IMI’s IP policy, the participants undertake to disseminate the data as soon as reasonably practicable but not later than one year after the termination or expiry of the project. The project agreement shall include a description of the material, which must be disseminated in accordance with the IP policy and referenced in the grant agreement. If the participants do not disseminate within such time periods without good reason, then the Executive Office has the right to disseminate such results in a manner consistent with the grant agreement.


PREDECT hopes to provide more appropriate in vitro platforms both for target validation and subsequent preclinical studies, which will replace a current cascade of tests that are poorly predictive of clinical activity. The project is expected to shift paradigms in cell biology as well as in preclinical target validation where it should permit greater predictivity of drug efficacy in patient cohorts.

Points of Contact

John Hickman
Institut de Recherche Servier
Rue de la République 3
92150 Suresnes, France

Ralph Graeser, Ph.D.
Janssen Pharmaceutica nv
Turnhoutseweg 30
Beerse, Belgium B-2340

Laurence Lapôtre
Senior Consultant, Kurt Salmon
Immeuble “Le Front de Parc,” 109, boulevard de Stalingrad
BP 11259, 69608 Villeurbanne cedex, France

Sponsors & Partners

AbbVie Inc.

AstraZeneca AB, Sweden

Bayer Schering Pharma AG, Germany

Biomedicum Genomics Ltd., Finland

Boehringer Ingelheim International GmbH, Germany

Catholic University Foundation, Netherlands

Ecole Polytechnique Fédérale de Lausanne, Switzerland

Erasmus University Medical Centre, Netherlands

F. Hoffmann-La Roche AG, Switzerland

Institut de Recherche Servier, France

Institute of Cancer Research, United Kingdom

Institute of Experimental Biology and Technology, Portugal 

Janssen Pharmaceutica NV

Oncotest GmbH, Germany

Orion Pharma, Finland

Robert Bosch Society for Medical Research mbH, Germany

Sigma-Tau S.p.A., Italy

Technical Research Centre of Finland

University of Helsinki, Finland

University of Tartu, Estonia

Weizmann Institute of Science, Israel

Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.